Figure 2.
Enrollment, follow-up, and pharmacokinetics (PK) inclusion criteria for study participants. FTC, emtricitabine; HIV, human immunodeficiency virus; PrEP, preexposure prophylaxis; TDF, tenofovir disoproxil fumarate; TFV, tenofovir.

Enrollment, follow-up, and pharmacokinetics (PK) inclusion criteria for study participants. FTC, emtricitabine; HIV, human immunodeficiency virus; PrEP, preexposure prophylaxis; TDF, tenofovir disoproxil fumarate; TFV, tenofovir.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close